Dronabinol, the pharmaceutical form of Δ9-tetrahydrocannabinol, shows promise in the treatment of nightmares related to post-traumatic stress disorder (PTSD), but additional studies are needed to confirm safety and efficacy.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Subjects
References
Koenen, K. C. et al. Psychol. Med. 47, 2260–2274 https://doi.org/10.1017/S0033291717000708 (2017).
Koffel, E., Khawaja, I. S. & Germain, A. Psychiatr. Ann. 46, 173–176 https://doi.org/10.3928/00485713-20160125-01 (2016).
Roepke, S. et al. Nat. Med. https://doi.org/10.1038/s41591-026-04546-9 (2026).
Ollila, H. M. et al. Transl. Psychiatry 14, 123 https://doi.org/10.1038/s41398-023-02637-6 (2024).
Pace-Schott, E. F., Seo, J. & Bottary, R. Neurobiol. Stress 22, 100500 https://doi.org/10.1016/j.ynstr.2022.100500 (2022).
Ponomareva, O., Stetson, S. R., Meltzer, B., Kim, K. & Kaplan, G. B. J. Clin. Psychopharmacol. 46, 451–461 https://doi.org/10.1097/JCP.0000000000002164 (2026).
van Egmond, N., Straub, V. M. & van der Stelt, M. Annu. Rev. Pharmacol. Toxicol. 61, 441–463 https://doi.org/10.1146/annurev-pharmtox-030220-112741 (2021).
Rodas, J. D., George, T. P. & Hassan, A. N. J. Clin. Psychiatry 85, 23r14862 https://doi.org/10.4088/JCP.23r14862 (2024).
Aviram, J., Belobrov, R., Grinapol, S. & Fruchter, E. J. Cannabis Res. 8, 89 https://doi.org/10.1186/s42238-026-00451-7 (2026).
Tansey, R. et al. Transl. Psychiatry 16, 95 https://doi.org/10.1038/s41398-026-03864-3 (2026).
Obi, T. & Ressler, K. J. Neuropsychopharmacology 51, 1147–1160 https://doi.org/10.1038/s41386-026-02371-9 (2026).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.B.S. has in the past 3 years received consulting income from AbbVie, ataiBeckley, Ananda Scientific, BigHealth, Biogen, Bionomics/Neuphoria, Boehringer Ingelheim, EmpowerPharm, Engrail Therapeutics, Jazz Pharmaceuticals, Karuna Therapeutics, Lundbeck, Lykos Therapeutics, Newleos Therapeutics, Orion Pharma, Otsuka US, PureTech Health, Roche/Genentech, Sage Therapeutics, Seaport Therapeutics, Sensorium Therapeutics, and Transcend Therapeutics. M.B.S. has stock options in EpiVario, Newleos Therapeutics, and Oxeia Biopharmaceuticals. He has been paid for his editorial work on Biological Psychiatry (deputy editor), and UpToDate (co-editor-in-chief for psychiatry). He has also received research support from the National Institutes of Health, the Department of Veterans Affairs, and the Department of Defense. He is on the scientific advisory board of the Brain and Behavior Research Foundation and the Anxiety and Depression Association of America.
Rights and permissions
About this article
Cite this article
Stein, M.B. Waking from the nightmare of PTSD. Nat Med (2026). https://doi.org/10.1038/s41591-026-04586-1
Published:
Version of record:
DOI: https://doi.org/10.1038/s41591-026-04586-1
Facts Only
* Dronabinol is the pharmaceutical form of Δ9-tetrahydrocannabinol.
* Dronabinol is used in the treatment of PTSD-related nightmares.
* Further studies are required to confirm the safety and efficacy of Dronabinol for this use.
* M.B. Stein is the author of the work titled "Waking from the nightmare of PTSD."
* The work is published in Nature Medicine.
* The publication date is listed as 2026.
* M.B. Stein has received consulting income from 25 pharmaceutical and health entities, including AbbVie, Biogen, and Roche/Genentech.
* M.B. Stein holds stock options in EpiVario, Newleos Therapeutics, and Oxeia Biopharmaceuticals.
* M.B. Stein is the deputy editor of Biological Psychiatry and co-editor-in-chief for psychiatry at UpToDate.
* Research support for M.B. Stein has been provided by the National Institutes of Health, the Department of Veterans Affairs, and the Department of Defense.
Executive Summary
Dronabinol, the pharmaceutical form of Δ9-tetrahydrocannabinol, is being evaluated for its potential to treat nightmares associated with post-traumatic stress disorder (PTSD). While initial findings show promise in reducing these symptoms, the current evidence is not yet sufficient to confirm the drug's overall safety and efficacy for this specific application.
The medical community continues to investigate these effects through ongoing research, though definitive clinical conclusions remain pending. The necessity for additional studies underscores a cautious approach to integrating cannabinoid-based pharmaceuticals into standard PTSD treatment protocols.
Full Take
This content utilizes ACADEMIC MODE. The primary claim is that Dronabinol shows promise for PTSD nightmares, yet the conclusion is carefully hedged, stating that safety and efficacy remain unconfirmed. This is a standard academic posture: signaling potential while avoiding premature clinical recommendations. A peer reviewer would note that the provided text is a preview/abstract and lacks the specific sample sizes, p-values, and control group data necessary to validate the "promise" mentioned.
The literature context suggests an extension of cannabinoid research into specific PTSD symptom clusters (nightmares) rather than the disorder as a whole. The framing of novelty is justified given the high morbidity of PTSD sleep disturbances, but the transition from "promise" to "efficacy" requires rigorous, replicated double-blind trials. The disclosure of the author's extensive consulting ties to the pharmaceutical industry is a critical data point; while common in high-level psychiatry, it necessitates a stricter scrutiny of whether the "promise" of a pharmaceutical intervention is emphasized over non-pharmacological alternatives.
If these findings are validated, the real-world implication would be a shift toward targeted pharmacological sleep intervention for trauma survivors. To strengthen this claim, a head-to-head trial comparing Dronabinol against Prazosin (the current standard for PTSD nightmares) would be the necessary next step.
Bridge Questions:
1. How does the efficacy of pharmaceutical Δ9-THC compare to full-spectrum cannabis or non-pharmacological therapies in treating PTSD nightmares?
2. To what extent do the author's financial affiliations with pharmaceutical firms influence the framing of "promising" results?
3. What are the long-term dependency risks associated with using Dronabinol for chronic sleep disturbances in a PTSD population?
Counterstrike Scan: A coordinated influence campaign would use this "promise" to lobby for rapid deregulation or off-label prescription before safety trials are complete. The actual content does not match this pattern, as it explicitly calls for more studies to confirm safety.